Skip to main content

Table 1 Demographics and clinical characteristics of subjects

From: Association of serum uric acid levels with COVID-19 severity

Factors Control group
(n = 273)
COVID-19
Total (n = 91) Moderate group (n = 69) Severe group (n = 22)
Age (years) 47.55 ± 15.33 47.53 ± 15.43 44.00 ± 14.32 58.59 ± 13.69†, ‡
Gender (male/female) 120/153 40/51 26/43 14/8
BMI (kg/m2) 23.58 ± 3.38 23.57 ± 3.49 23.18 ± 3.41 24.95 ± 3.49
HGB (g/L) 141.99 ± 13.60 138.23 ± 17.39 138.48 ± 16.61 137.45 ± 20.34
LEU*(*109/L) 1.73 ± 0.24 1.59 ± 0.32 1.59 ± 0.32 1.58 ± 0.32
LYM% 35.92 ± 7.90 32.54 ± 10.46 34.17 ± 9.72 27.43 ± 11.27†, ‡
eGFR* (ml/min*1.73m2) 4.70 ± 0.15 4.66 ± 0.15 4.68 ± 0.15 4.57 ± 0.13†, ‡
AST* (U/L) 3.06 ± 0.29 3.03 ± 0.39 2.96 ± 0.36 3.24 ± 0.41†, ‡
ALB/GLB 1.74 ± 0.24 1.35 ± 0.22 1.38 ± 0.22 1.24 ± 0.18 †, ‡
α-HBDH* (U/L) 4.91 ± 0.17 4.90 ± 0.23 4.84 ± 0.20 5.06 ± 0.24†, ‡
LDH* (U/L) 5.14 ± 0.18 5.14 ± 0.25 5.08 ± 0.22 5.32 ± 0.26†, ‡
FPG (mmol/L) 4.66 (4.39–5.05) 5.31 (4.890–6.18) 5.06 (4.830–5.81) 5.80 (5.340–7.36) †, ‡
PaO2/FiO2* 5.94 ± 0.53 6.19 ± 0.25 5.12 ± 0.36
Days from onset to admission 3.0 (1.0–6.0) 3.0 (1.00–6.0) 4.0 (1.750–6.0)
Days from admission to PCR negative) 9.0 (4.00–13.0) 8.0 (4.00–10.0) 11.50 (4.750–20.75)
Diabetic patients (%) 0 9 (9.9) 4 (5.8) 5 (22.7)
Gout patients (%) 0 0   
Hypertensive patients (%) 0 17 (18.7) 10 (14.5) 7 (31.8)
UA* (μmol/L)
 Total 5.80 ± 0.24 5.65 ± 0.28 5.66 ± 0.29 5.62 ± 0.25
 Male 5.95 ± 0.18 5.78 ± 0.26 5.86 ± 0.20 5.61 ± 0.28†, ‡
 Female 5.68 ± 0.21 5.55 ± 0.26 5.53 ± 0.26 5.63 ± 0.20
Creatinine* (μmol/L)
 Total 4.14 ± 0.20 4.10 ± 0. 26 4.08 ± 0.27 4.16 ± 0.22
 Male 4.31 ± 0.13 4.30 ± 0.21 4.32 ± 0.22 4.26 ± 0.19
 Female 4.01 ± 0.14 3.94 ± 0.18 3.93 ± 0.19 4.00 ± 0.15
UA/Cr ratio*
 Total 1.65 ± 0.20 1.55 ± 0.27 1.58 ± 0.24 1.45 ± 0.32
 Male 1.64 ± 0.20 1.48 ± 0.28 1.54 ± 0.23 1.35 ± 0.34†, ‡
 Female 1.67 ± 0.21 1.60 ± 0.24 1.60 ± 0.25 1.63 ± 0.18
  1. Abbreviations: BMI Body mass index, HGB Hemoglobin, LEU Leukocyte, LYM Lymphocyte, eGFR Estimated glomerular filtration rate, AST Aspartic transaminase, ALB Albumin, GLB Globulin, α-HBDH α-hydroxybutyrate dehydrogenase, LDH Lactate dehydrogenase, FPG Fasting plasma glucose, UA Uric acid, Cr Creatinine
  2. Note: Data were expressed as the mean ± standard deviation (SD) or median (P25–P75). Days (from onset to admission): the days from symptom appearance to hospitalization, days (from admission to PCR negative): the days from hospitalization to result of nucleic acid of SARS-CoV-2 negative
  3. a*: The data were transformed into Ln (a)
  4. Compared with the control group: P < 0.05 labeled as ;
  5. Compared with the moderate group: P < 0.05 labeled as